New vaccine targets 26 pneumococcal strains in early trial
NCT ID NCT06703203
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase I/II trial tested a new 26-valent pneumococcal conjugate vaccine in 450 people aged 2 months and older. The goal was to check safety and how well the vaccine triggers an immune response compared to existing vaccines. Researchers monitored side effects and antibody levels after vaccination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
26-valent pneumococcal conjugate vaccine
What this could lead to
If successful, this vaccine could protect against more types of pneumococcal bacteria than current vaccines, potentially reducing pneumonia and ear infections.
What could go wrong
This is an early-phase trial focused on safety and immune response, not yet proven to prevent disease. Side effects like injection site pain or fever are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL VACCINES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Provincial Center for Disease Control and Prevention
Shangqiu, Henan, 476700, China